Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Falls 82.9%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 5,915 shares, a decrease of 82.9% from the August 31st total of 34,593 shares. Currently, 0.4% of the shares of the company are short sold. Based on an average daily volume of 38,250 shares, the days-to-cover ratio is currently 0.2 days.

Global X Genomics & Biotechnology ETF Price Performance

Shares of Global X Genomics & Biotechnology ETF stock traded down $0.84 during trading on Friday, hitting $69.41. 2,685 shares of the company’s stock traded hands, compared to its average volume of 18,194. Global X Genomics & Biotechnology ETF has a 1 year low of $37.25 and a 1 year high of $70.73. The business has a 50-day simple moving average of $61.21 and a 200-day simple moving average of $52.78. The stock has a market capitalization of $104.12 million, a P/E ratio of -29.66 and a beta of 1.19.

Institutional Trading of Global X Genomics & Biotechnology ETF

A hedge fund recently raised its position in Global X Genomics & Biotechnology ETF stock. Bank of America Corp DE lifted its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 67.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 119,795 shares of the company’s stock after acquiring an additional 48,394 shares during the quarter. Bank of America Corp DE owned 10.70% of Global X Genomics & Biotechnology ETF worth $5,240,000 as of its most recent filing with the Securities & Exchange Commission. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.